Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.

Oncotarget - 16 Aug 2016

Ling Yun, Yang Xin, Li Wenbin, Li Zhuo, Yang Lin, Qiu Tian, Guo Lei, Dong Lin, Li Lin, Ying Jianming, Lin Dongmei

Abstract excerpt

BACKGROUND: Epidermal growth factor receptor (EGFR) is a novel target for therapy in a subset of non-small cell lung cancer (NSCLC). Tumors with EGFR mutations showed good response to EGFR tyrosine kinase inhibitors (TKIs). We aimed to identify the discriminating capacity of immunohistochemistry (IHC) to detect EGFR L858R and del E746-A750 mutations in NSCLC patients and predict EGFR TKIs response. METHODS: We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gefitinib

Share to Kaplan-Meier Estimate

Share to Multivariate Analysis

Share to Outcome Assessment, Health Care

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 27418143
DOI: 10.18632/oncotarget.10594
PMCID: PMC5288154

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.PMID 27418143Read ↗

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.Semantic proximity Read ↗

The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer.Semantic proximity Read ↗

Ascertaining an appropriate diagnostic algorithm using EGFR mutation-specific antibodies to detect EGFR status in non-small-cell lung cancer.Semantic proximity Read ↗

Diagnostic value of mutation-specific antibodies for immunohistochemical detection of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

[Value of immunohistochemical staining with mutation-specific antibodies in detecting EGFR mutations: a meta-analysis].Semantic proximity Read ↗

[Immunohistochemical detections of EGFR status in NSCLC].Semantic proximity Read ↗

Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?Semantic proximity Read ↗

[Immunohistochemical detections of EGFR mutations in NSCLC].Semantic proximity Read ↗

Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer.Semantic proximity Read ↗

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.Semantic proximity Read ↗

Immunohistochemistry for EGFR Mutation Detection in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Clinicopathologic Features and Molecular Biomarkers as Predictors of Epidermal Growth Factor Receptor Gene Mutation in Non-Small Cell Lung Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.